A Pharmacokinetic Study of Genasense® (Bcl-2 Antisense Oligonucleotide) in Combination With Dacarbazine (DTIC) in Subjects With Advanced Melanoma and Normal or Impaired Hepatic Function
Interventional
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Pharmacokinetics of G3139
6-day period
No
United States: Food and Drug Administration
GPK103
NCT00543205
August 2005
May 2007
Name | Location |
---|